[EN] PYRIDYL DERIVATIVES, THEIR PREPARATION AND USE<br/>[FR] DÉRIVÉS DE PYRIDYLE, LEUR PRÉPARATION ET UTILISATION.
申请人:PIRAMAL LIFE SCIENCES LTD
公开号:WO2009019656A1
公开(公告)日:2009-02-12
The present invention relates to pyridyl derivatives capable of inhibiting phosphatidylinositol-3-kinase (PI3k), mammalian target of rapamycin (mTOR) and/or hypoxia inducible factor 1α (HIF-1α) mediated signaling. Also disclosed are processes for preparation of the pyridyl derivatives, and their use in the manufacture of pharmaceutical compositions for the treatment of clinical conditions caused by deregulation of signaling pathways selected from one or more of PI3K, mTOR and HIF-1α pathways. The pyridyl derivatives are also useful for the treatment of conditions or disorders mediated by TNF-α.
The present invention relates to pyridyl derivatives capable of inhibiting phosphatidylinositol-3-kinase (PI3k), mammalian target of rapamycin (mTOR) and/or hypoxia inducible factor 1α (HIF-1α) mediated signaling. Also disclosed are processes for preparation of the pyridyl derivatives, and their use in the manufacture of pharmaceutical compositions for the treatment of clinical conditions caused by deregulation of signaling pathways selected from one or more of PI3K, mTOR and HIF-1α pathways. The pyridyl derivatives are also useful for the treatment of conditions or disorders mediated by TNF-α.
Deore, Vijaykumar; Bhonde, Mandar R.; Vishwakarma, Ram A., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2009, vol. 48, # 12, p. 1761 - 1765
Synthesis and therapeutic evaluation of pyridyl based novel mTOR inhibitors
作者:Vijaykumar Deore、Nilambari Yewalkar、Dimple Bhatia、Nikesh Desai、Ravindra D. Gupte、Shruta S. Dadarkar、Mahesh G. Jadhav、Aditi A. Tannu、Pooja Bhatt、Kumar V.S. Nemmani、Ram A. Vishwakarma、Somesh Sharma、Abhijit Roychowdhury、Nilesh M. Dagia、Mandar R. Bhonde、Sanjay Kumar
DOI:10.1016/j.bmcl.2009.04.055
日期:2009.6
A series of novel cyanopyridyl based molecules (1-14) were designed, synthesized and probed for inhibition of mammalian target of rapamycin (mTOR) activity. Compound 14 was found to be a potent inhibitor of mTOR activity as assessed by enzyme-linked immunoassays and Western blot analysis. Most importantly, systemic application (intraperitoneal; ip) of compound 14 significantly suppressed macroscopic and histological abnormalities associated with chemically-induced murine colitis. (C) 2009 Elsevier Ltd. All rights reserved.